跳至主要内容
临床试验/ACTRN12608000582358
ACTRN12608000582358
进行中(未招募)
未知

A Prospective, Randomised, Multicentre Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of up to two De Novo Coronary Artery Lesions

Boston Scientific Corporation0 个研究点目标入组 1,532 人2008年11月19日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Atherosclerotic lesions in the coronary artery
发起方
Boston Scientific Corporation
入组人数
1532
状态
进行中(未招募)
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2008年11月19日
结束日期
待定
最后更新
6年前
研究类型
Interventional
性别
All

研究者

入排标准

入选标准

  • 1\. Patient is eligible for percutaneous coronary intervention (PCI)
  • 2\. Patient has documented stable angina pectoris, or documented silent ischaemia, or unstable angina pectoris
  • 3\. Patient is acceptable candidate for Coronary Artery Bypass Graft (CABG)
  • 4\. Patient has left ventricular ejection fraction of \>30%
  • 5\. Target lesion must be de novo and located within native coromary artery with diameter \>2\.50mm and \<4\.25mm
  • 6\. Target lesion must be \<24mm in length
  • 7\. Target lesion must be in a major coronary artery or branch with visually estimated stenosis \>50% and \<100%

排除标准

  • 1\. Clinical symptoms or Electrocardiogram (ECG) changes consistent with Myocardial Infarction (MI)
  • 2\. Patient has known diagnosis of recent MI (within 30 days prior to index procedure) and has elevated enzymes at time of index procedure
  • 3\. Target vessel or side branch treated with any type of PCI within 12 months prior to index procedure
  • 4\. Patient is receiving chronic anticoagulation therapy for indications other than acute coronary syndrome

结局指标

主要结局

未指定

相似试验